Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 10 July 2017 Biocartis and A*STAR’s ETPL initiate development of breast cancer assay to guide therapy selection Non-regulated information 13 June 2017 Biocartis launches CE-marked IVD test for lung cancer Idylla™ EGFR Mutation Test is the only on market fully automated CE-IVD test detecting all relevant EGFR mutations according to international guidelines Non-regulated information 13 June 2017 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 7 June 2017 MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform Non-regulated information 2 June 2017 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 23 May 2017 Biocartis launches CE-marked IVD NRAS test for colorectal cancer Non-regulated information 18 May 2017 Study demonstrating high performance of Idylla™ liquid biopsy RAS tests to be presented at ASCO Annual Meeting Non-regulated information 12 May 2017 Results of the annual shareholders’ meeting held on 12 May 2017 Regulated information 10 May 2017 Biocartis announces its new CEO Inside information Regulated information 27 April 2017 Biocartis Q1 2017 Business Update Regulated information Pagination First page « First Previous page ‹‹ … Page 22 Page 23 Page 24 Page 25 Current page 26 Page 27 Page 28 Page 29 Page 30 … Next page ›› Last page Last »